Cost-Effectiveness of Nivolumab (NIVO) Combined with Ipilimumab (IPI) Compared with Nivo and Ipi Monotherapies in The First-Line Treatment of Advanced Melanoma in The United States- Analysis Using 28-Month Overall Survival (OS) Data from Ch ...
Abstract
Authors
T Baker VF Paly J Sabater K Gupte-Singh H Beyhaghi S Kotapati S Rao A Briggs